History

2011

 

April 28 - The official date of NANOLEK foundation

 

 

 

2012

 

July 26 – The beginning of construction of the NANOLEK industrial complex in the Kirov region; the groundbreaking ceremony with the participation of the Governor of the Kirov region N.Y. Belykh

November 15 – Signing of the agreement with Bilthoven Biologicals (the Netherlands) on the development, transfer of technology and organization of production of the first domestically developed inactivated polio vaccine

December 27 – NANOLEK receives a Patronage Certificate from the Kirov region Governor as one of the most promising investment projects

 

 

 

2013

 

April – NANOLEK and BIOCOM win contests of the Russian Ministry of Industry and Trade for the development and production of anti-tumor drugs such as Procarbazine and Lomustine, as well as remedies for the treatment of leukemia such as Tretinoin and Hydroxychloroquine

July 30 – NANOLEK and GC Epidiomed win a competition of the Russian Ministry of Industry and Trade for transfer of foreign development of recombinant influenza vaccine based on virus-like particles produced by using the lentivirus vector

 

 

 

2014

 

December 23 – Obtaining the license of the Russian Ministry of Industry and Trade for the production of sterile and non-sterile drugs; the official ceremony of the start of production of solid dosage forms (building 5)

 

 

 

2015

 

March 26 -  Signing of the agreement with Green Cross biotechnology company (Green Cross, Korea) on strategic partnership in the development and manufacture of high-tech biopharmaceuticals

June – The beginning of mass production of solid dosage forms on the basis of the NANOLEK plant in the Kirov region

June 19 – Signing of the agreement with Sanofi Pasteur on the localization of production of Pentaxim, a five-component combined vaccine

September 7 – Signing of the agreement with Pharmaceutical Plant Egis and Celltrion (Korea) on the localization of the medicine for the treatment of rheumatoid arthritis - biosimilar infliximab - Flammegis®

September 19 – Obtaining Russian and international ISO 9001 quality certificates

October 2 – Signing of the agreement with Merck on the localization of production of drugs for the treatment of diabetes and cardiovascular diseases (Glucophage, Concor)

 

 

 

2016

 

March 17 – Signing of the agreement with the largest company in the South Africa - Aspen - for the production of injectable anticoagulants (Fraxiparine (nadroparin calcium) and for the transfer of a unique production technology

3rd quarter – The launch of production of biopharmaceuticals (building 4)

April 22 – Obtaining a Patronage Certificate of the Governor of the Kirov region N.Y. Belykh